ArticleJournal of diabetes research2026
Medicaid CGM Barriers in Blind/Low Vision and Deaf/Hard of Hearing Populations.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medicaid CGM Barriers in Blind/Low Vision and Deaf/Hard of Hearing Populations.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continuous glucose monitors (CGMs) are essential tools for diabetes management; however, many state Medicaid programs do not have standardized, inclusive policies that ensure equitable access to CGMs for blind/low vision (BLV) and deaf/hard of hearing (DHH) populations, driving disparities across the United States and its territories. This policy analysis examines the barriers and facilitators to Medicaid CGM coverage for BLV and DHH populations, specifically in Medicaid and non-Medicaid expansion states, and patient choice in CGM device selection. CGM barrier language existed in 9.6% of states and U.S. territories, preventing BLV and DHH populations from accessing CGM. Facilitator language was present in 5.8% of states and U.S. territories, advocating for equitable access to CGMs for BLV individuals but not DHH individuals. Given the limitations of CGM alarms, this paper also emphasizes the need for Medicaid to cover secondary devices that provide needed haptic, visual, and audible alarms as necessary accessibility tools rather than optional add-ons. These devices are integral to ensuring a safe and independent CGM use for BLV and DHH individuals. Policy changes that prioritize health equity, framing CGM access as both a usability issue and a matter of eligibility for all Medicaid beneficiaries, is crucial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.